30 January 2020 
EMA/CHMP/55667/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
MabThera 
rituximab 
On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
MabThera. The marketing authorisation holder for this medicinal product is Roche Registration GmbH. 
The CHMP adopted new indications as follows: 
“MabThera, in combination with glucocorticoids, is indicated for the induction of remission in 
paediatric patients (aged ≥2 to <18 years old) with severe, active GPA (Wegener’s) and MPA.” 
and 
“MabThera, in combination in combination with chemotherapy is indicated for the treatment of 
paediatric patients (aged ≥6 months  to <18 years old) with previously untreated advanced stage 
CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia 
(mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).” 
For information, the full indications for MabThera will be as follows: 
“Non-Hodgkin’s lymphoma (NHL) 
MabThera is indicated for the treatment of previously untreated adult patients with stage III-IV 
follicular lymphoma in combination with chemotherapy.  
MabThera maintenance therapy is indicated for the treatment of adult follicular lymphoma 
patients responding to induction therapy.  
MabThera monotherapy is indicated for treatment of adult patients with stage III-IV follicular 
lymphoma who are chemoresistant or are in their second or subsequent relapse after 
chemotherapy.  
MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell 
non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisolone) chemotherapy.  
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients 
(aged ≥6 months  to <18 years old) with previously untreated advanced stage CD20 positive 
diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell 
acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL). 
Chronic lymphocytic leukaemia (CLL) 
MabThera in combination with chemotherapy is indicated for the treatment of patients with 
previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and 
safety for patients previously treated with monoclonal antibodies including MabThera or patients 
refractory to previous MabThera plus chemotherapy. 
See section 5.1 for further information. 
Rheumatoid arthritis 
MabThera in combination with methotrexate is indicated for the treatment of adult patients with 
severe active rheumatoid arthritis who have had an inadequate response or intolerance to other 
disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor 
(TNF) inhibitor therapies. 
MabThera has been shown to reduce the rate of progression of joint damage as measured by X-
ray and to improve physical function, when given in combination with methotrexate. 
Granulomatosis with polyangiitis and microscopic polyangiitis  
MabThera, in combination with glucocorticoids, is indicated for the treatment of adult patients 
with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic 
polyangiitis (MPA). 
MabThera, in combination with glucocorticoids, is indicated for the induction of remission in 
paediatric patients (aged ≥2 to <18 years old) with severe, active GPA (Wegener’s) and MPA. 
Pemphigus vulgaris 
MabThera is indicated for the treatment of patients with moderate to severe pemphigus vulgaris 
(PV).” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
MabThera  
EMA/CHMP/55667/2020 
Page 2/2 
 
  
  
 
 
